Business
Akebia is a biopharmaceutical company focused on kidney disease, with commercial products Auryxia and Vafseo plus a pipeline of kidney and other programs.
Akebia revenue rose 47.5% to $236.2M and free cash flow swung to $67.7M as Vafseo added scale.
The read at a glance✓ Audited against SEC data
- Business mix — Kidney-disease biopharma with Auryxia and VafseoNote
- Revenue — Revenue rose 47.5% to $236.2MOK
- Cash — Free cash flow was $67.7MOK
- Profitability — Operating income turned positiveOK
- Balance sheet — Equity improved to $32.6MOK
- Insiders — 1 buy / 6 sellsNote
- Accounting — Altman-Z distress; EQ greyWatch
Where the revenue comes from
Fiscal 2025, as Akebia Therapeutics, Inc. reports it. History and quarterly detail are in the app.
- Product revenue, net$227.3M
- Auryxia$181.5M
- Vafseo$45.8M
- License, collaboration and other revenue$8.9M
- License Collaboration And Other Revenue, Royalties$1.8M
Leadership changes
From Akebia Therapeutics, Inc.'s own filings, the day they're filed.
- Ellen Snow · President · appointmenteff. 2023-07-17
- Merrimack College · Directors · appointment
- John Butler · Chief Executive Officer · departure
Latest filings
- 10-Q · Quarterly report2026-08-05
- 8-K · Company announcement2026-08-05
- 8-K · Company announcement2026-06-30
- 8-K · Company announcement2026-06-22
- 10-Q · Quarterly report2026-05-07
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Akebia Therapeutics, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.